New targeted therapies for renal cell carcinoma

Bibliography

• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996;335:865-75
   PubMed Web of Science ®Google Scholar
• Leibovich BC, Han KR, Bui MH, Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003;98:2566-75
   PubMed Web of Science ®Google Scholar
• Reuter VE. The pathology of renal epithelial neoplasms. Semin Oncol 2006;33:534-43
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bacik J, Mariani T, Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002;20:2376-81
   PubMed Web of Science ®Google Scholar
• Harris DT. Hormonal therapy and chemotherapy of renal-cell carcinoma. Semin Oncol 1983;10:422-30
   PubMed Web of Science ®Google Scholar
• Yagoda A, Bander NH. Failure of cytotoxic chemotherapy, 1983-1988, and the emerging role of monoclonal antibodies for renal cancer. Urol Int 1989;44:338-45
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bacik J, Murphy BA, Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289-96
   PubMed Web of Science ®Google Scholar
• Coppin C, Porzsolt F, Awa A, Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005:CD001425
   PubMed Web of Science ®Google Scholar
• McDermott DF, GM, Signoretti S, Ghebremichael MS, The high-dose aldesleukin ‘SELECT’ trial in patients with metastatic renal cell carcinoma. J Clin Oncol 2010;28: abstract 4514
   PubMedGoogle Scholar
• Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004;22:4991-5004
   PubMed Web of Science ®Google Scholar
• Senger DR, Van de Water L, Brown LF, Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 1993;12:303-24
   PubMed Web of Science ®Google Scholar
• Kaelin WG Jr. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res 2007;13:680s-684s
   PubMed Web of Science ®Google Scholar
• Kamura T, Sato S, Iwai K, Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA 2000;97:10430-5
   PubMed Web of Science ®Google Scholar
• Ohh M, Park CW, Ivan M, Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000;2:423-7
   PubMed Web of Science ®Google Scholar
• Maxwell PH, Wiesener MS, Chang GW, The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-5
   PubMed Web of Science ®Google Scholar
• Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005;353:172-87
   PubMed Web of Science ®Google Scholar
• Knebelmann B, Ananth S, Cohen HT, Sukhatme VP. Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor. Cancer Res 1998;58:226-31
   PubMed Web of Science ®Google Scholar
• Ananth S, Knebelmann B, Gruning W, Transforming growth factor beta1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma. Cancer Res 1999;59:2210-16
   PubMed Web of Science ®Google Scholar
• Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12:9-22
   PubMed Web of Science ®Google Scholar
• Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 2001;98:10983-5
   PubMed Web of Science ®Google Scholar
• Fresno Vara JA, Casado E, de Castro J, PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004;30:193-204
   PubMed Web of Science ®Google Scholar
• Porta C, Figlin RA. Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors. J Urol 2009;182:2569-77
   PubMed Web of Science ®Google Scholar
• Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005;24:7455-64
   PubMed Web of Science ®Google Scholar
• Averous J, Proud CG. When translation meets transformation: the mTOR story. Oncogene 2006;25:6423-35
   PubMed Web of Science ®Google Scholar
• Hudson CC, Liu M, Chiang GG, Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002;22:7004-14
   PubMed Web of Science ®Google Scholar
• van der Heijden MS, Bernards R. Inhibition of the PI3K pathway: hope we can believe in? Clin Cancer Res 2010;16:3094-9
   PubMed Web of Science ®Google Scholar
• Parsons DW, Jones S, Zhang X, An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-12
   PubMed Web of Science ®Google Scholar
• Edgren M, Lennernas B, Larsson A, Nilsson S. Serum concentrations of VEGF and b-FGF in renal cell, prostate and urinary bladder carcinomas. Anticancer Res 1999;19:869-73
   PubMed Web of Science ®Google Scholar
• Sato K, Tsuchiya N, Sasaki R, Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma. Jpn J Cancer Res 1999;90:874-9
   PubMedGoogle Scholar
• Abrams TJ, Lee LB, Murray LJ, SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003;2:471-8
   PubMed Web of Science ®Google Scholar
• O'Farrell AM, Abrams TJ, Yuen HA, SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101:3597-605
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L, BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109
   PubMed Web of Science ®Google Scholar
• Castaneda CA, Gomez HL. Pazopanib: an antiangiogenic drug in perspective. Future Oncol 2009;5:1335-48
   PubMed Web of Science ®Google Scholar
• Harris PA, Boloor A, Cheung M, Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-m ethyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem 2008;51:4632-40
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J, Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:1061-8
   PubMed Web of Science ®Google Scholar
• Inai T, Mancuso M, Hashizume H, Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004;165:35-52
   PubMed Web of Science ®Google Scholar
• Rugo HS, Herbst RS, Liu G, Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005;23:5474-83
   PubMed Web of Science ®Google Scholar
• Rixe O, Bukowski RM, Michaelson MD, Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 2007;8:975-84
   PubMed Web of Science ®Google Scholar
• Rini BI, Wilding G, Hudes G, Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009;27:4462-8
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bacik J, Schwartz LH, Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22:454-63
   PubMed Web of Science ®Google Scholar
• Jonasch E, BA, Chen Y, Bair A, Axitinib with or without dose titration as first-line therapy for metastatic renal cell carcinoma (mRCC). J Clin Oncol 2010;28: abstract TPS235
   Web of Science ®Google Scholar
• Pfizer announces positive Phase 3 trial results for axitininb in patients with previously-treated metastatic renal cell carcinoma. Available from: www.news-medical.net/news/20101120/Pfizers-Phase-3-AXIS-1032-trial-for-metastatic-renal-cell-carcinoma-meets-primary endpoint. [Last accessed 22 March 2011]
   Google Scholar
• Eskens F, dJM, Esteves B, de Jonge M, Updated results from a Phase I study of AV-951 (KRN951), a potent and selective VEGFR-1, -2 and -3 tyrosine kinase inhibitor, in patients with advanced solid tumors [abstract LB-201]. Annual Meeting of the American Association for Cancer Research 2008; 2008
   Google Scholar
• Bhargava P, EB, Nosov DA, Esteves B, Updated activity and safety results of a Phase II randomised discontinuation trial (RDT) of AV-951, a potent and selective VEGFR1, 2 and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC). J Clin Oncol 2009;27: abstract 5032
   PubMed Web of Science ®Google Scholar
• Bhargava P, EB, Al-Adhami M, Esteves B, Activity of tivozanib (AV-951) in patients with renal cell carcinoma (RCC): subgroup analysis from a phase II randomized discontinuation trial (RDT). J Clin Oncol 2010;28: abstract 4599
   PubMed Web of Science ®Google Scholar
• Lee SH, Lopes de Menezes D, Vora J, In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin Cancer Res 2005;11:3633-41
   PubMed Web of Science ®Google Scholar
• Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309
   PubMed Web of Science ®Google Scholar
• Lopes de Menezes DE, Peng J, Garrett EN, CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia. Clin Cancer Res 2005;11:5281-91
   PubMed Web of Science ®Google Scholar
• Sarker D, Molife R, Evans TR, A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin Cancer Res 2008;14:2075-81
   PubMed Web of Science ®Google Scholar
• Angevin E, LJ, Pande A, Lopez JA, TKI258 (dovitinib lactate) in metastatic renal cell carcinoma (mRCC) patients refractory to approved targeted therapies: A phase I/II dose finding and biomarker study. J Clin Oncol 2009;27: abstract 3563
   Web of Science ®Google Scholar
• Drevs J, Siegert P, Medinger M, Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007;25:3045-54
   PubMed Web of Science ®Google Scholar
• Sridhar SS, HS, Mackenzie MJ, Hotte SJ, Phase II study of the angiogenesis inhibitor AZD2171 in first line, progressive, unresectable, advanced metastatic renal cell carcinoma (RCC): a trial of the PMH Phase II consortium. J Clin Oncol 2007;25: abstract 5093
   Google Scholar
• Mulders P, HR, Nathan P, Hawkins R, Final results of a Phase II randomised study of cediranib (RECENTIN™) in patients with advanced renal cell carcinoma (RCC). Eur J Cancer Suppl 2009;7: abstract 49LBA
   Google Scholar
• Albert DH, Tapang P, Magoc TJ, Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther 2006;5:995-1006
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Dumas J, Adnane L, Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal, and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 2010 [Epub ahead of print]
   Google Scholar
• Wong CI, Koh TS, Soo R, Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. J Clin Oncol 2009;27:4718-26
   PubMed Web of Science ®Google Scholar
• Tannir NM, WY, Kollmannsberger CK, Wong Y, Phase II trial of linifanib in patients with advanced renal cell cancer after sunitinib failure. J Clin Oncol 2010;28: abstract 4527
   Google Scholar
• Eisen T, JH, Nathan P, Joensuu H, Phase II trial of the oral multikinase inhibitor BAY 73-4506 as 1st-line therapy in patients with metastatic or unresectable renal cell carcinoma (RCC). Eur J Cancer Suppl 2009b;7: abstract 7.105
   Google Scholar
• Hudes G, Carducci M, Tomczak P, Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56
   PubMed Web of Science ®Google Scholar
• Sun SY, Rosenberg LM, Wang X, Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005;65:7052-8
   PubMed Web of Science ®Google Scholar
• Wan X, Harkavy B, Shen N, Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007;26:1932-40
   PubMed Web of Science ®Google Scholar
• Wang X, Yue P, Chan CB, Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation. Mol Cell Biol 2007;27:7405-13
   PubMed Web of Science ®Google Scholar
• Serra V, Markman B, Scaltriti M, NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008;68:8022-30
   PubMed Web of Science ®Google Scholar
• Cho DC, Cohen MB, Panka DJ, The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res 2010;16:3628-38
   PubMed Web of Science ®Google Scholar
• Chiorean EG, MD, Harris WB, Mahadevan D, Phase I evaluation of SF1126, a vascular targeted P13K inhibitor, administered twice weekly IV in patients with refractory solid tumors. J Clin Oncol 2009;27: abstract 2558
   Web of Science ®Google Scholar
• Brana I, LP, Baselga J, LoRusso P, A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a P13K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced malignancies. J Clin Oncol 2010;28: abstract 3030
   PubMed Web of Science ®Google Scholar
• Vjaz A. Phosphatidyl 3-kinase (P13K) inhibitors as anticancer drugs. Drugs Fut 2007;32:537
   Web of Science ®Google Scholar
• Edelman G, BC, Shapiro G, Bedell C, A phase I dose-escalation study of XL147 (SAR245408), a P13K inhibitor adminstered orally to patients (pts) with advanced malignancies. J Clin Oncol 2010;28: abstract 3004
   PubMed Web of Science ®Google Scholar
• Kondapaka SB, Singh SS, Dasmahapatra GP, Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2003;2:1093-103
   PubMed Web of Science ®Google Scholar
• Schreeder MT, FR, Stephenson JJ, Figlin RA, Phase I multicenter trial of perifosine in combination with sorafenib for patients with advanced cancers including renal cell carcinoma. J Clin Oncol 2008;26: abstract 16024
   Web of Science ®Google Scholar
• Holland WS, MP, Gandara DR, Mack PC, Preclinical rationale for combination targeted therapy in advanced clear cell renal cell carcinoma (RCC): abrogation of rapamycin-mediated induction of AKT phosphorylation by perifosine. J Clin Oncol 2008;26: abstract 16083
   Web of Science ®Google Scholar
• Crul M, RH, de Klerk GJ, Rosing H, Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur J Cancer 2002;38:1615
   PubMed Web of Science ®Google Scholar
• Van Ummersen L, BK, Volkman J, Binger K, A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patient with advanced cancer. Clin Cancer Res 2004;10:7450
   PubMed Web of Science ®Google Scholar
• Stephenson J, SM, Waples J, Schreeder M, Perifosine (P), active as a single agent for renal cell carcinoma (RCC), now in phase I trials combined with tyrosine kinase inhibitors (TKI). J Clin Oncol 2007;25: abstract 15622
   Google Scholar
• Cho DC, FR, Flaherty KT, Figlin RA, A phase II trial of perifosine in patients with advanced renal cell carcinoma (RCC) who have failed tyrosine kinase inhibitors (TKI). J Clin Oncol 2009;27: abstract 5101
   Google Scholar
• Tolcher AW, YT, Fearen I, Yap TA, A phase I study of MK-2206, an oral potent allosteric Akt inhibitor (Akti) in patients (pts) with advanced solid tumor (ST). J Clin Oncol 2009;27: abstract 3503
   PubMed Web of Science ®Google Scholar
• Tan DS, DH, Olmos D, Dumez H, First-in-human phase I study exploring three schedules of OSI-027, a novel small molecule TORC1/TORC2 inhibitor, in patients with advanced solid tumors and lymphoma. J Clin Oncol 2010;28: abstract 3006
   Web of Science ®Google Scholar
• Dong H, Strome SE, Salomao DR, Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793-800
   PubMed Web of Science ®Google Scholar
• Thompson RH, Kuntz SM, Leibovich BC, Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006;66:3381-5
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Drake CG, Wollner I, Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28:3167-75
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000;163:408-17
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ. Another step toward the cure of metastatic renal cell carcinoma? J Clin Oncol 2010;28:5017-19
   PubMed Web of Science ®Google Scholar
• Rini BI, Vogelzang NJ, Dumas MC, Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol 2000;18:2419-26
   PubMed Web of Science ®Google Scholar
• Tannir NM, Thall PF, Ng CS, A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol 2008;180:867-72; discussion 872
   PubMed Web of Science ®Google Scholar
• Waters JS, Moss C, Pyle L, Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma. Br J Cancer 2004;91:1763-8
   PubMed Web of Science ®Google Scholar
• Stadler WM, Halabi S, Rini B, A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008. Cancer 2006;107:1273-9
   PubMed Web of Science ®Google Scholar
• Van Veldhuizen PJ, Hussey M, Lara PN Jr, A Phase II study of gemcitabine and capecitabine in patients with advanced renal cell cancer: southwest oncology group study S0312. Am J Clin Oncol 2009 [Epub ahead of print]
   Google Scholar
• Bellmunt J, Trigo JM, Calvo E, Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06). Lancet Oncol 2010;11:350-7
   PubMed Web of Science ®Google Scholar
• Richey SL, Ng C, Lim ZD, Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy. J Clin Oncol 2010 [Epub ahead of print]
   Google Scholar
• Naito S, Eto M, Shinohara N, Multicenter phase II trial of S-1 in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 2010;28:5022-9
   PubMed Web of Science ®Google Scholar
• Naito S, Tsukamoto T, Usami M, An early phase II trial of S-1 in Japanese patients with cytokine-refractory metastatic renal cell carcinoma. Cancer Chemother Pharmacol 2010;66:1065-70
   PubMed Web of Science ®Google Scholar
• Naito S, Yamamoto N, Takayama T, Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur Urol 2010;57:317-25
   PubMed Web of Science ®Google Scholar
• Larkin J, Gore M. Is advanced renal cell carcinoma becoming a chronic disease? Lancet 2010;376:574-5
   PubMed Web of Science ®Google Scholar
• Huang D, Ding Y, Zhou M, Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 2010;70:1063-71
   PubMed Web of Science ®Google Scholar
• Sosman JA, Puzanov I, Atkins MB. Opportunities and obstacles to combination targeted therapy in renal cell cancer. Clin Cancer Res 2007;13:764s-769s
   PubMed Web of Science ®Google Scholar
• Swanton C, Larkin JM, Gerlinger M, Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets. Genome Med 2010;2:53
   PubMed Web of Science ®Google Scholar